Amphastar Pharmaceuticals (AMPH) Change in Receivables (2013 - 2026)

Amphastar Pharmaceuticals has reported Change in Receivables for 14 years, with the latest figure at -$3.0 million in Q2 2026.

• On a quarterly basis, Change in Receivables rose 75.72% year-over-year to -$3.0 million in Q2 2026; TTM through Jun 2026 was $12.1 million, a 1167.19% increase from a year earlier, with the FY2025 full-year figure at $6.4 million, down 70.62% from the prior year.
• Change in Receivables was -$3.0 million for Q2 2026 at Amphastar Pharmaceuticals, down from $4.5 million in the prior quarter.
• The five-year high for Change in Receivables was $23.2 million in Q1 2024, with the low at -$12.3 million in Q2 2025.
• Average Change in Receivables over 5 years is $3.7 million, with a median of $1.6 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Change in Receivables jumped 1430.46% in 2022, then slumped 428.82% in 2024.
• Over 5 years, Change in Receivables stood at $11.6 million in 2022, then sank by 135.39% to -$4.1 million in 2023, then advanced by 28.93% to -$2.9 million in 2024, then retreated by 11.22% to -$3.2 million in 2025, then climbed by 7.83% to -$3.0 million in 2026.
• The last three Change in Receivables figures came in at -$3.0 million (Q2 2026), $4.5 million (Q1 2026), and -$3.2 million (Q4 2025), per Business Quant data.